TG-1701-101
11 Nov 2020
Trial Summary
This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton’s Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies.
Acronym:
TG-1701-101
ACTRN/NCT /ethics:
NCT03671590
Scientific title:
Study of TG-1701, an irreversible Bruton’s Tyrosine Kinase inhibitor, in patients with B-cell malignancies
Sponsor / Cooperative group:
TG Therapeutics Inc.
Trial & Patient Characteristics
| Cancer Type | Lymphoma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Lymphoma |
| Cancer Stage | Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2018-09-10 |
| Anticipated End Date | 2020-09-01 |
Participating Hospitals
| Hospital | Ashford Cancer Centre Research |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| syeend@adelaidecancercentre.com.au | |
| Phone | 08 8292 2240 |
| Principal Investigator | Dr Stanley Cheung |
| Recruitment Status | Recruiting |